DRE’s DOC Analytics™ Generates First-Ever Automated Network Meta-Analysis with Natural Language Question AI-Powered Search Results
Summary
SANTA MONICA, Calif.--(BUSINESS WIRE)--Doctor Evidence (DRE) has updated their newly launched DOC Analytics™ (“Digital Outcome Conversion”) platform with industry standard network meta-analysis (NMA) capabilities. With the addition of indirect treatment comparison and landscape analysis using NMA, DOC Analytics™ is a critical, daily-use tool for strategic functions in life sciences companies. As the “new normal” reality requires companies to do “more with less,” and organizations adopt distributed working models as a standard practice, technology is needed to accelerate the speed at which decisions are made. The healthcare industry is at the intersection of newly available technologies, now critically relevant for business decisions in the context of exponential growth of clinical trials, RWE, and associated publications. This is transformational in allowing mission-critical work functions across life science companies to receive immediate analytics, including product lifecycle management, clinical trial planning and design, therapeutic landscape surveillance, medical planning and communication, and benefit-risk analysis,” said DRE’s Chief Executive Officer, Bob Battista, MBA, FRCPH, FRCP Edin.